UNSPSC 51162507: Benzocaine/dextromethorphan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51162507 Benzocaine/dextromethorphan is a Commodity code covering pharmaceutical and over-the-counter products procured by state and local health agencies, though recent activity shows the code is being applied to a broader range of health-related pharmaceuticals and drug-intervention products than the specific code name suggests. State and local issuing bodies acquiring under this code include county health departments, state cooperative purchasing alliances, and multistate purchasing consortiums. Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement (administering the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) represent recent active buyers, with MMCAP serving participating state and local government facilities across multiple states including Oregon.

Recent opportunities under the code span naloxone procurement for community health initiatives and broad-based generic pharmaceutical distribution. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, all inclusive of shipping costs, under a two-year term with one-year renewal option. The Minnesota Department of Administration issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) through MMCAP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), with awards effective July 1, 2026 and contract terms of two years for new vendors. The MMCAP solicitation emphasizes cGMP and Drug Supply Chain Security Act compliance, wholesale distribution partnerships, and pricing flexibility across net-price and WAC-minus formats, with evaluation weighted 75 percent on price competitiveness.